1
项与 Treprostinil prodrug subcutaneous(United Therapeutics) 相关的临床试验A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose titration regimens of subcutaneous Remodulin infusion in subjects with pulmonary arterial hypertension (PAH). The study will include about 50 subjects at up to 10 clinical trial centers in China. The treatment phase of the study will last approximately 16 weeks. Subjects who complete all required assessments will also be eligible to enter a long-term open-label, extension study (CVT-CV-004).
100 项与 Treprostinil prodrug subcutaneous(United Therapeutics) 相关的临床结果
100 项与 Treprostinil prodrug subcutaneous(United Therapeutics) 相关的转化医学
100 项与 Treprostinil prodrug subcutaneous(United Therapeutics) 相关的专利(医药)
100 项与 Treprostinil prodrug subcutaneous(United Therapeutics) 相关的药物交易